"We found that we needed to
do something from a formulary standpoint and notify plans about the potential
abuse of certain drugs. If I was a fraudster, I would target high-cost drugs."
— Jo-Ellen
Abou Nader, vice president of fraud, waste, and abuse and supply chain
optimization at Prime Therapeutics LLC, spoke with AIS's Health Plan Weekly about
the PBM's new data analytics platform to help identify and weed out fraud,
waste and abuse.
No comments:
Post a Comment